肝细胞癌辅助治疗研究进展和挑战
Advances and challenges of adjuvant treatment in hepatocellular carcinoma
寻琛 1秦叔逵1
作者信息
- 1. 211112 南京 中国药科大学附属第一医院 南京天印山医院
- 折叠
摘要
肝细胞癌(HCC)是全球常见且我国高发的恶性肿瘤.肝切除术、物理消融和肝移植术是根治早中期HCC最有效的方法,但是高复发率显著影响了治疗的总体效果.近年来,晚期HCC的治疗研究陆续取得成功,促进了对于肝癌辅助治疗的积极探索.本文全面综述了HCC辅助治疗研究的现状及其进展,对存在的挑战进行了深刻思考,希望为相关临床工作者提供参考.
Abstract
Hepatocellular carcinoma(HCC)is a common malignant tumor in the whole world,and has a high incidence in China.Hepatectomy,physical ablation and liver transplantation are the most effective radical methods for early and middle stage HCC,but the high recurrence rate significantly affects the patients′ overall survival.In recent years,there have been successive breakthroughs in the treatment of advanced HCC,which has stimulated active exploration of adjuvant therapy for HCC.This paper provides a comprehensive review of the current status and progress of adjuvant therapy for HCC,and deeply reflects on the challenges that exist.It is hoped that this paper can provide reference for clinicians.
关键词
肝细胞癌/辅助治疗/局部治疗/系统治疗/免疫检查点抑制剂Key words
Hepatocellular carcinoma/Adjuvant therapy/Local treatment/Systematic treatment/Immune checkpoint inhibitors引用本文复制引用
出版年
2024
NETL
NSTL
万方数据